Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

BUY
$11.61 - $15.22 $586,781 - $769,234
50,541 New
50,541 $587,000
Q2 2022

Aug 09, 2022

SELL
$14.32 - $19.88 $186,689 - $259,175
-13,037 Closed
0 $0
Q1 2022

May 11, 2022

BUY
$15.39 - $20.25 $200,639 - $263,999
13,037 New
13,037 $252,000
Q3 2021

Nov 12, 2021

SELL
$13.06 - $17.24 $282,553 - $372,987
-21,635 Closed
0 $0
Q2 2021

Aug 05, 2021

BUY
$11.45 - $13.96 $247,720 - $302,024
21,635 New
21,635 $290,000
Q1 2020

May 12, 2020

SELL
$8.11 - $15.23 $330,004 - $619,723
-40,691 Closed
0 $0
Q4 2019

Feb 12, 2020

BUY
$10.28 - $14.38 $109,019 - $152,499
10,605 Added 35.25%
40,691 $576,000
Q3 2019

Nov 12, 2019

SELL
$10.05 - $14.55 $294,927 - $426,984
-29,346 Reduced 49.38%
30,086 $317,000
Q2 2019

Aug 06, 2019

SELL
$13.1 - $14.95 $341,294 - $389,492
-26,053 Reduced 30.48%
59,432 $865,000
Q1 2019

May 15, 2019

BUY
$13.69 - $20.06 $146,619 - $214,842
10,710 Added 14.32%
85,485 $1.2 Million
Q4 2018

Feb 12, 2019

SELL
$13.96 - $18.26 $325,268 - $425,458
-23,300 Reduced 23.76%
74,775 $1.31 Million
Q3 2018

Nov 13, 2018

SELL
$13.63 - $15.7 $365,284 - $420,760
-26,800 Reduced 21.46%
98,075 $1.5 Million
Q2 2018

Aug 09, 2018

SELL
$13.44 - $17.59 $1.41 Million - $1.84 Million
-104,621 Reduced 45.59%
124,875 $1.72 Million
Q1 2018

May 11, 2018

BUY
$13.8 - $16.99 $542,284 - $667,639
39,296 Added 20.66%
229,496 $3.83 Million
Q4 2017

Feb 14, 2018

BUY
$11.73 - $14.75 $1.31 Million - $1.64 Million
111,500 Added 141.68%
190,200 $2.7 Million
Q3 2017

Nov 20, 2017

BUY
$12.06 - $14.12 $949,122 - $1.11 Million
78,700
78,700 $1.11 Million

Others Institutions Holding INVA

About Innoviva, Inc.


  • Ticker INVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 69,706,000
  • Market Cap $1.21B
  • Description
  • Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a ...
More about INVA
Track This Portfolio

Track Gsa Capital Partners LLP Portfolio

Follow Gsa Capital Partners LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Gsa Capital Partners LLP with notifications on news.